AASLD & Partner Organizations Sound the Alarm: Reverse ACIP’s Hepatitis B Birth Dose Rollback Now
The American Association for the Study of Liver Diseases (AASLD) and its undersigned partner organizations, American College of...
AASLD Announces Update to Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Practice Guidance
New guidance provides clinicians with practical, evidence-based criteria for patient selection, comorbidity management, and...
Statement from AASLD: AASLD Acknowledges Withdrawal of Obeticholic Acid for Primary Biliary Cholangitis and Announces Upcoming Guideline Update
The American Association for the Study of Liver Diseases (AASLD) acknowledges the recent market withdrawal of obeticholic acid...
AASLD Announces New Practice Guideline on Treatment of Chronic Hepatitis B
The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) are...
Hepatitis B
AASLD develops evidence-based practice guidelines which are updated regularly by a multi-disciplinary panel of experts, including hepatologists, and include recommendations of preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. AASLD also provides practice tools to assist with learning and implementing the new recommendations.
AASLD Announces the 2025 Distinguished Advocacy Award Recipient
AASLD proudly recognizes the Department of Veterans Affairs (VA) Hepatitis Innovation Team (HIT) and the HIT collaborating...